By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

FibroGen, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-7200 Fax: 650-866-7202


SEARCH JOBS


Industry
Biotechnology






Company News
FibroGen, Inc.Announces One-Year Data Supporting The Safety And Efficacy Profile Of FG-3019 In Patients With Idiopathic Pulmonary Fibrosis 9/22/2014 10:48:44 AM
FibroGen, Inc. Announces Results Of Phase 2 Study Of FG-3019 Indicating Positive Activity Against Pancreatic Cancer 6/2/2014 9:41:35 AM
Bay Area's FibroGen, Inc. Touts Phase 2 Data For Idiopathic Pulmonary Fibrosis Drug FG-3019 5/19/2014 6:44:21 AM
FibroGen, Inc. Announces Patient Enrollment In New Phase 2 Clinical Study Of FG-3019 For The Treatment Of Idiopathic Pulmonary Fibrosis 12/20/2013 9:43:04 AM
FibroGen, Inc. Announces Observations Of Possible Disease Stabilization And Improvement In Interim Analysis Of Phase 2 Study Of FG-3019 As Treatment For Idiopathic Pulmonary Fibrosis 11/27/2013 8:53:53 AM
FibroGen, Inc. Reports Data From Phase 2 Hemoglobin Correction Study of Roxadustat (FG-4592) in Chinese Patients With Chronic Kidney Disease 11/12/2013 11:27:09 PM
FibroGen, Inc. Announces Analysis Of Peritoneal Dialysis Patients With Chronic Kidney Disease From Roxadustat (FG-4592) Incident Dialysis Study 11/12/2013 11:16:43 PM
FibroGen, Inc. to Present Data for Roxadustat (FG-4592), an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Oral Presentations at American Society of Nephrology - Kidney Week 2013 11/5/2013 7:08:37 AM
AstraZeneca PLC (AZN) Bets $815 Million on FibroGen, Inc.'s Anemia Drug 7/31/2013 6:45:26 AM
FibroGen, Inc. and Astellas Pharma Inc. (YPH.BE) Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease 12/12/2012 9:26:14 AM
12345678
//-->